Table 1 Baseline characteristics of age and sex matched cohorts before IPTW.
| Â | Non-sinusitis cohort | Sinusitis cohort | ASD |
|---|---|---|---|
| Â | 263,064 | 131,532 | Â |
Year of index | |||
 2002–2004 | 123,302 (46.87%) | 61,651 (46.87%) | < 0.01 |
 2005–2007 | 54,036 (20.54%) | 27,018 (20.54%) | < 0.01 |
 2008–2010 | 33,116 (12.59%) | 16,558 (12.59%) | < 0.01 |
 2011–2013 | 27,136 (10.32%) | 13,568 (10.32%) | < 0.01 |
 2014–2016 | 14,930 (5.68%) | 7465 (5.68%) | < 0.01 |
 2017–2019 | 10,544 (4.01%) | 5272 (4.01%) | < 0.01 |
Sex | |||
 Male | 130,106 (49.46%) | 65,053 (49.46%) | < 0.01 |
 Female | 132,958 (50.54%) | 66,479 (50.54%) | < 0.01 |
Age at T0 | |||
 < 40 | 170,891 (64.96%) | 86,300 (65.61%) | 0.01 |
 40–49 | 41,808 (15.89%) | 19,815 (15.06%) | 0.02 |
 50–59 | 31,052 (11.80%) | 15,566 (11.83%) | < 0.01 |
 60–69 | 13,527 (5.14%) | 6935 (5.27%) | 0.01 |
 70–79 | 4616 (1.75%) | 2312 (1.76%) | < 0.01 |
 ≥ 80 | 1170 (0.44%) | 604 (0.46%) | < 0.01 |
Urbanization level | |||
 1 (high) | 80,612 (30.64%) | 41,470 (31.53%) | 0.02 |
 2 | 76,778 (29.19%) | 39,804 (30.26%) | 0.02 |
 3 | 43,570 (16.56%) | 23,177 (17.62%) | 0.03 |
 4 | 37,196 (14.14%) | 17,061 (12.97%) | 0.03 |
 5 | 4846 (1.84%) | 1908 (1.45%) | 0.03 |
 6 | 11,690 (4.44%) | 4502 (3.42%) | 0.05 |
 7 (low) | 8372 (3.18%) | 3610 (2.74%) | 0.03 |
Type of insurance coverage | |||
 Government | 17,179 (6.53%) | 9755 (7.42%) | 0.03 |
 Labor | 151,916 (57.75%) | 84,238 (64.04%) | 0.13 |
 Farmers’/fishermen’s membership | 36,091 (13.72%) | 15,643 (11.89%) | 0.05 |
 Low-income households | 1831 (0.70%) | 587 (0.45%) | 0.03 |
 Non-labor force/unemployed | 49,122 (18.67%) | 19,252 (14.64%) | 0.11 |
 Others | 6925 (2.63%) | 2057 (1.56%) | 0.07 |
 Length of hospital stay (within 180 days before T0) | |||
 0 day | 260,868 (99.17%) | 129,579 (98.52%) | 0.06 |
 1–6 days | 1264 (0.48%) | 1429 (1.09%) | 0.07 |
 >=7 days | 932 (0.35%) | 524 (0.40%) | 0.01 |
Co-morbidity (within 180 days before T0) | |||
 Hypertension | 14,694 (5.59%) | 10,390 (7.90%) | 0.09 |
 Diabetes mellitus | 6447 (2.45%) | 3997 (3.04%) | 0.04 |
 Hyperlipidemia | 7174 (2.73%) | 5706 (4.34%) | 0.09 |
 Ischemic heart diseases | 3123 (1.19%) | 2547 (1.94%) | 0.06 |
 Peripheral vascular disease | 327 (0.12%) | 247 (0.19%) | 0.02 |
 Ischemic stroke | 1262 (0.48%) | 739 (0.56%) | 0.01 |
 Hemorrhagic stroke | 404 (0.15%) | 153 (0.12%) | 0.01 |
 Chronic kidney disease | 871 (0.33%) | 448 (0.34%) | < 0.01 |
 COPD | 2211 (0.84%) | 3778 (2.87%) | 0.15 |
 Alcohol-related disorders | 899 (0.34%) | 602 (0.46%) | 0.02 |
 Rheumatoid arthritis | 340 (0.13%) | 295 (0.22%) | 0.02 |
 Systemic lupus erythematosus | 136 (0.05%) | 99 (0.08%) | 0.01 |
Co-medication (within 180 days before T0) | |||
 Systemic corticosteroids | 8668 (3.30%) | 13,634 (10.37%) | 0.28 |
 NSAIDs | 47,371 (18.01%) | 64,671 (49.17%) | 0.70 |
 Beta- blockers | 7552 (2.87%) | 5700 (4.33%) | 0.08 |
 CCBs | 7981 (3.03%) | 5662 (4.30%) | 0.07 |
 ACEI | 2851 (1.08%) | 1965 (1.49%) | 0.04 |
 ARBs | 4641 (1.76%) | 3201 (2.43%) | 0.05 |
 Statin | 3078 (1.17%) | 2278 (1.73%) | 0.05 |
 Diuretics | 454 (0.17%) | 322 (0.24%) | 0.02 |
 Vitamin K antagonists | 310 (0.12%) | 162 (0.12%) | < 0.01 |
 Heparin preparations | 192 (0.07%) | 126 (0.10%) | 0.01 |
